Articles & Whitepapers
Researchers agree that early detection is the key to optimising the potential success of drug and device therapies – and that these therapies would work most effectively if they were administered when a patient first begins to develop a disease rather than waiting until when they are displaying obvious symptoms. However, it is extremely difficult to observe exactly when this process starts ...
Guidance development process How we develop NICE medical technologies guidance NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for ...
Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
Signifier Medical Technologies LLC, a Boston-based medical technology company, announced today that the Centers for Medicare & Medicaid Services (CMS) established two new Level II Healthcare Common Procedure Coding System (HCPCS) codes to ...
PreludeDx Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
Women’s Health and AI, CureMetrix Joins Forces with AuntMinnie.com and AuntMinnieEurope.com for Virtual Conference
Equipment & Solutions
The ClarityDX® Platform is designed to measure the patient’s disease state. Detecting biomarkers for disease in biofluid samples shows that the patients’ cells are expressing organ-specific and disease-associated proteins.